Germany’s Merck KGaA (MRK: DE) took in 5.3 billion euros ($5.8 billion) sales in the first quarter of 2023, a little short of many analysts’ expectations, a 1.8% increase from the same period of 2022.
With post-tax profits hitting 800 million euros, the earnings per share figure was 9.4% lower than in the first quarter of last year, at 1.83 euros.
Merck was propelled by a good performance in its healthcare division, which delivered significant increases in its business with new medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze